NewAmsterdam Pharma (NAMSW) Expected to Announce Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMSW) is anticipated to release its results before the market opens on Wednesday, August 12th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.4726) per share and revenue of $1.8770 million for the quarter.

NewAmsterdam Pharma Stock Performance

Shares of NAMSW opened at $15.00 on Wednesday. The company has a 50-day simple moving average of $20.90 and a two-hundred day simple moving average of $21.72. NewAmsterdam Pharma has a one year low of $10.27 and a one year high of $30.45.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. purchased a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,708 shares of the company’s stock, valued at approximately $397,000.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.